Background: The "gold standard" approach for diagnosing myocardial infarction (MI) in patients with a high risk of the condition is cardiac troponins T or I (cTnT or cTnI), which are more accurate than CK-MB for myocardial damage. In addition to these well-known biomarkers, several intriguing biomarkers have gained attention in MI over the past few years. Soluble suppression of tumorigenicity-2 (sST-2), also known as Interleukin-1 receptor-like 1 (IL-1RL-1) is one of such biomarkers. Aim: this study aimed to assess the association of sST-2 with acute MI among Egyptian population. Patients and methods:A total of 72 individuals were enrolled in the study, including thirty-six patients with MI and thirty-six healthy normal controls. sST-2 was measured by ELISA in both groups. sST-2 was measured in patients with MI at two occasions: during first 24 hours of chest pain and 30 days after. Results: sST-2 level was higher in MI patients compared to normal controls. The level of sST-2 declined after 30 days after attack compared to day one. A positive correlation was found between serum level of sST-2 and cardiac marker of necrosis: serum CK (r = 0.65, p <0.001), CK-MB (r= 0.51, p= 0.001), and LDH (r= 057, p < 0.001). Soluble ST-2 was negatively correlated with ventricular ejection fraction (r= -0.40, p=0.015). We found that a cut-off value of 150 pg/ml for sST-2 denoted the presence of MI with 86.11% sensitivity and 80.56% specificity (p < 0.001). ROC curve was plotted for serum sST-2 to indicate the development of complications after MI sets a threshold value of 3100 pg/ml with 90% sensitivity and 96.15% specificity (p < 0.001). Conclusions: sST-2 is a potential biomarker for acute myocardial infarction (AMI) and possible predictors for the risk of myocardial damage in the Egyptian population.